Online citations, reference lists, and bibliographies.
← Back to Search

„Genitourinary Syndrome Of Menopause“ – Vaginale Östrogene Im Vergleich

P. Stute
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Das „genitourinary syndrome of menopause“ (GSM) beschreibt östrogenmangelassoziierte vulvovaginale und urologische Symptome. Jede zweite Frau ist nach der Menopause davon betroffen. Verschiedene vaginale Östrogenpräparate in unterschiedlicher Dosierung stehen für die GSM-Therapie zur Verfügung. Die „Östrogenität“ eines Präparats hängt allerdings nicht allein von der Dosis und der Art des Östrogens ab, sondern ist das Ergebnis des/der individuellen Östrogenrezeptor(ER)-Polymorphismus, -Expression und -Affinität, der lokalen Enzymausstattung, des Metabolismus und der Konzentration von Bindungsproteinen. Der Artikel beschreibt detailliert die auf dem Schweizer Markt erhältlichen vaginalen Östrogenprodukte. The genitourinary syndrome of menopause (GSM) describes vulvovaginal and urological symptoms associated with estrogen deficiency. Every second woman is affected by GSM after the menopause. Various vaginal estrogen preparations in different concentrations are available for treatment of GSM; however, the “estrogenicity” of a product is not only dependent on the dose and the type of estrogen but also on various factors such as the individual expression of estrogen receptor (ER), ER polymorphism and affinity, locally available enzymes, metabolism and concentration of binding proteins. This article describes all vaginal estrogen products available on the Swiss market in detail. Le syndrome génito-urinaire de la ménopause (SGM) comprend un ensemble de symptômes vulvo-vaginaux et urologiques associés au déficit en œstrogènes. Une femme sur deux en souffre après la ménopause. Différentes préparations vaginales d’œstrogènes à différents dosages sont disponibles pour le traitement du SGM. La puissance des effets œstrogéniques d’une préparation dépend toutefois non seulement de la dose et du type d’œstrogène, mais aussi des propriétés des récepteurs d’œstrogène (ERs) chez la personne individuelle (polymorphisme, expression et affinité des récepteurs), des enzymes localement présentes, du métabolisme et de la concentration en protéines de liaison. L’article décrit en détail les préparations vaginales d’œstrogènes disponibles sur le marché suisse.
This paper references
10.1007/s001290050341
Pharmakologie von Sexualsteroiden
H. Kuhl (1998)
Aktuelle Empfehlungen zur Menopausalen Hormon-Therapie (MHT). Expertenbrief, Bd. 42. Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe
10.1210/endo.138.3.4979
Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β.
G. Kuiper (1997)
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
G. Kuiper (1997)
10.1111/jsm.12686
Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
D. Portman (2014)
10.1016/J.JMIG.2004.12.024
Yen and Jaffe's Reproductive Endocrinology
S. Corson (2005)
AWMF (2019) Peri-and Postmenopause-Diagnosis and Interventions
10.1080/13697130500148875
Pharmacology of estrogens and progestogens: influence of different routes of administration
H. Kuhl (2005)
Genitourinary syndrome of
DJ Portman (2014)
Pharmacology of estrogens and Gestagens. In: Fischl F (Hrsg) Menopause – Andropause: hormone replacement therapy through the ages
H Kuhl (2001)
10.1186/s12884-016-0937-5
Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study
H. Schock (2016)
2016) Menopause: diagnosis and management of menopause. (NICE guideline)
MA Lumsden (2016)
10.1016/j.maturitas.2016.06.001
Revised global consensus statement on menopausal hormone therapy.
T. D. de Villiers (2016)
Vulvovaginal complaints. In: Lobo RA (Hrsg) Treatment of the postmenopausal women. Basic and clinical aspects
G A Bachmann (1994)
10.1080/13697137.2016.1222483
The NICE Guideline – Menopause: diagnosis and management
M. Lumsden (2016)
Pharmacology of estrogens and Gestagens
GG Kuiper (2001)
10.1016/j.jsxm.2017.01.011
The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.
M. Krychman (2017)
Klimakterium, Postmenopause und Hormonsubstitution.UNI-MED,Bremen
H Kuhl (2006)
10.1016/j.maturitas.2014.07.013
Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
D. Portman (2014)
Women’s voices in the menopause: results from an international survey on vaginal atrophy.Maturitas
RE Nappi (2010)
10.1016/j.maturitas.2016.06.018
A model of care for healthy menopause and ageing: EMAS position statement.
P. Stute (2016)
10.1016/j.maturitas.2010.08.001
Women's voices in the menopause: results from an international survey on vaginal atrophy.
R. Nappi (2010)
Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral
Verlags Hinweis Des
Dayto-day impact of vaginal aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and wellbeing in postmenopausal women
AJ Huang (2015)
10.1097/GME.0000000000000281
Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women
A. Huang (2015)
Pierroz DD (2016) Revised global Journal für Gynäkologische Endokrinologie/Schweiz 1 · 2020 9 consensus statement on menopausal hormone
TJ de Villiers (2020)
Menopause : diagnosis and management of menopause . ( NICE guideline )
A Lethaby (2016)
10.1097/GME.0b013e3182a122c2
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society
G. Bachman (2013)
10.1210/jc.2015-2236
Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.
C. Stuenkel (2015)
10.1056/NEJMRA000471
Production and actions of estrogens.
C. Gruber (2002)
10.1016/0378-5122(81)90041-4
Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol.
A. Haspels (1981)
Pharmacology of estrogens and Gestagens
H Kuhl (2001)
10.1097/GME.0000000000000921
The 2017 hormone therapy position statement of The North American Menopause Society
J. A. Pinkerton (2017)
Aktuelle Empfehlungen zur Menopausalen Hormon-Therapie (MHT). Expertenbrief, Bd
M Birkhäuser (2015)
Pierroz DD (2016) Revised global Journal für Gynäkologische Endokrinologie/Schweiz Menopause consensus statement on menopausal hormone
TJ de Villiers (2016)
Productionandactionsof estrogens
TschugguelW GruberCJ
10.1002/14651858.CD001500.pub3
Local oestrogen for vaginal atrophy in postmenopausal women.
A. Lethaby (2016)



Semantic Scholar Logo Some data provided by SemanticScholar